WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
1. (WO1997026887) USE OF GALANTHAMINE IN THE PREPARATION OF NOVEL DRUGS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1997/026887    International Application No.:    PCT/AT1997/000011
Publication Date: 31.07.1997 International Filing Date: 27.01.1997
Chapter 2 Demand Filed:    26.08.1997    
IPC:
A61K 31/55 (2006.01)
Applicants: SANOCHEMIA LTD. [MT/MT]; 136 St. Christopher Street, Valetta (MT) (For All Designated States Except US).
MUCKE, Martin, Alois, Hermann [AT/AT]; (AT) (For US Only).
FRANTSITS, Werner [AT/AT]; (AT) (For US Only)
Inventors: MUCKE, Martin, Alois, Hermann; (AT).
FRANTSITS, Werner; (AT)
Agent: BEER, Otto; Lindengasse 8, A-1070 Wien (AT)
Priority Data:
A 149/96 26.01.1996 AT
Title (DE) VERWENDUNG VON GALANTHAMIN ZUM HERSTELLEN VON NEUEN ARZNEIMITTELN
(EN) USE OF GALANTHAMINE IN THE PREPARATION OF NOVEL DRUGS
(FR) UTILISATION DE GALANTHAMINE POUR PREPARER DE NOUVEAUX MEDICAMENTS
Abstract: front page image
(DE)Verwendung von Galanthamin oder eines Säureadditionssalzes desselben zum Herstellen eines Arzneimittels zur Behandlung von Trisomie 21 und verwandten Syndromen, zur Behandlung des Glaukoms, für die Behandlung der Myasthenia gravis sowie mit dieser verwandter neuromuskulärer Autoimmunkrankheiten und/oder für die Behandlung des Nervenkompressionstraumas.
(EN)Described is the use of galanthamine or one of its acid addition salts in the preparation of a drug for the treatment of trisomia 21 and related syndromes, glaucoma, myasthenia gravis and neuromuscular auto-immune illnesses and/or nerve-compression trauma.
(FR)L'invention concerne l'utilisation de galanthamine ou d'un de ses sels d'addition d'acide pour préparer un médicament s'utilisant dans le traitement de la trisomie 21 et des syndromes apparentés, pour traiter le glaucome, la myasthénie grave, ainsi que les maladies neuromusculaires auto-immunes apparentées et/ou le traumatisme de compression nerveuse.
Designated States: AU, BR, CA, CN, CZ, EE, HU, IL, IS, JP, KR, LT, LV, NO, NZ, PL, RU, SG, SI, SK, TR, UA, US.
European Patent Office (EPO) (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
Publication Language: German (DE)
Filing Language: German (DE)